The Evolving Role of Systemic Therapy in Nasopharyngeal Carcinoma: Current Strategies and Perspectives
Chapter in an edited book (author)


Times Cited
Altmetrics Information
.

Other information
AbstractTreatment for nasopharyngeal carcinoma (NPC) has evolved tremendously over the last decade, owing to the integration of chemotherapy into the primary radiotherapy, improvement in tumor imaging and disease monitoring, and advances in high precision radiotherapy delivery. Several randomized trials have established concurrent chemoradiation (with or without adjuvant chemotherapy) as the standard of care in advanced NPC. Current efforts are building on these earlier trials, to further test the optimal strategy of integrating neoadjuvant or adjuvant chemotherapy to further improve patient’s survival and quality of life. Meanwhile investigators are developing novel and molecular targeted therapies in locoregionally advanced or metastatic NPC. This chapter will provide a basic understanding of the clinical data fromrandomized chemotherapy trials in NPC, current effort to integrate neoadjuvant chemotherapy to concurrent chemo-radiation in advanced NPC, and selection of high risk NPC by molecular marker of minimal residual disease for adjuvant therapy. On-going clinical studies in molecular targeted therapies in NPC, including the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), epigenetic therapy, Epstein-Barr virus (EBV) directed immunotherapy and gene therapy, will also be discussed.
All Author(s) ListHui EP, Chan ATC
All Editor(s) ListPierre Busson
Journal nameAdvances in Experimental Medicine and Biology
Book titleNasopharyngeal Carcinoma: Keys for Translational Medicine and Biology
Series TitleAdvances in Experimental Medicine and Biology
Year2013
Volume Number778
PublisherSPRINGER, 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
Pages149 - 172
ISBN978-1-4614-5946-0
eISBN978-1-4614-5947-7
ISSN0065-2598
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology;Medicine, Research & Experimental;Oncology;Research & Experimental Medicine

Last updated on 2021-20-06 at 23:44